Lunit, an "AI Cancer Comprehensive Company," Aims to Achieve 10 Trillion KRW in Sales in 10 Years

10th Anniversary Meeting
"Platform Development as the Future Direction"

Covers All Anticancer Biomarkers
From Platform Utilization to New Drug Development

"Until now, Lunit has been a company creating AI applications (apps), and while we will continue to do so, developing an AI platform will be our future direction." (Beomseok Seo, CEO of Lunit)

Marking its 10th anniversary, the medical artificial intelligence (AI) company Lunit presented a mid- to long-term vision aiming for "annual sales of 10 trillion KRW and operating profit of 5 trillion KRW" by its 20th anniversary in 2033. In addition to its core business of cancer diagnosis, it outlined plans for big data business, comprehensive biomarker development, and even new drug development.

Seo Beom-seok, CEO of Lunit, is giving a greeting at a press conference held at Lunit Square in Gangnam-gu, Seoul, on the morning of the 24th.
[Photo by Lee Chun-hee]

At the 10th anniversary meeting held on the morning of the 24th at Lunit Square in Gangnam-gu, Seoul, CEO Beomseok Seo stated, "Based on AI technology in which domestic companies have particular strengths, we will enhance the quality of medical services at healthcare institutions worldwide and increase cancer patient survival rates, thereby realizing the founding spirit and corporate philosophy of 'conquering cancer through AI.'"

Lunit plans to go beyond its existing core business of 'AI solutions' for cancer diagnosis and treatment to create a 'data-AI virtuous cycle ecosystem' through data. To this end, it presented goals including a medical big data platform, autonomous AI, whole-body magnetic resonance imaging (MRI), multi-omics biomarkers, and discovery of new drug candidate substances.

First, in the big data platform sector, Lunit will promote integrated management of medical big data to improve cancer diagnosis and treatment prediction accuracy based on AI. Data will be collected from screening centers, regional base hospitals, clinical trial institutions, and cancer centers worldwide and subjected to precise analysis through AI learning models. Subsequently, an integrated AI platform will be developed to be directly installed and managed within medical institution systems.

Regarding AI technology advancement, Lunit will embark on developing autonomous AI that can make judgments independently. This technology will enable AI to diagnose on its own, raising AI reading accuracy to 100%, allowing AI to independently interpret images.

Additionally, whole-body MRI technology will be developed. The intention is to enable screening for all cancers in the entire body with a single imaging session. Compared to existing imaging diagnostics, it is expected to have higher detection rates, lower false-positive rates, and no radiation exposure risk, making it a next-generation solution. Moreover, considering that half of all cancer types are not even screened in current screening environments, the ability to detect all cancers early is expected to have a significant impact.

Lunit's Cancer Treatment Business Development Model
Photo by Lunit

The existing flagship product, 'Lunit Scope,' will expand its utilization to include antibody-drug conjugates (ADC), currently the most notable anticancer modality (treatment approach). Ultimately, the plan is to develop biomarkers for all anticancer drugs. Recently, at an academic conference, results were announced showing that using Lunit Scope to check patient biomarker levels significantly improved the therapeutic efficacy of ADCs.

In terms of biomarkers, development applying a multi-omics approach is also underway. Multi-omics refers to various analyses and approaches for disease research, including genomics and microbiology. By integrating pathology and medical imaging learning, it aims to enable higher prediction accuracy of anticancer drug treatment effects, contributing to optimal drug selection.

Furthermore, Lunit aims to transform into a new drug candidate development company. If positive results are derived by applying Lunit Scope to promising candidate substances, the technology will be licensed in, followed by direct development for either self-commercialization or technology export (license out) to other major pharmaceutical companies, establishing a business model of this nature.

This content was produced with the assistance of AI translation services.